MIMESIS

NEWSLETTER #2 / DECEMBER 2017

ENYO PHARMA

ENYO Pharma is completing the scaling-up of its innovative drug discovery approach with the MIMESIS project.

With €3.6 million spending over 24 months, ENYO Pharma will optimize at least five therapeutic starting points to modulate the function of novel human targets. This holds the promise of new drug development for many indications with unmet need.

MIMESIS Timeline & Current Status



After one year, ENYO Pharma has achieved great first results:

Design of a unique library

The MIMESIS library, inspired by viral strategies to modulate host cell biology, is a unique compound collection enriched with a higher than expected percentage of active molecules.

Completion of primary screenings

Three primary phenotypic screens are now completed; Respiratory Syncytial Virus (RSV), Zika virus and Triple negative Breast cancer (induction of Immunogenic Cell Death – ICD).

ENYO Pharma has already defined a list of more than 50 active small molecule structures and a second wave of primary screens on Human RhinoVirus (HRV), Influenza virus (Flu) and *Mycobacterium tuberculosis* (TB) will be completed by the end of 2017.

Validation of hits

Hit validation has been completed on the output from the RSV, Zika Virus and ICD screens.

ENYO Pharma confirmed the validity of a high proportion of primary hits and activity of structural analogues has been confirmed in the original screening assay.

A second wave of hit validation will be completed by Q1 2018 on HRV, Flu and TB.

Prioritization of validated hits

ENYO Pharma has selected several top priority hit chemical series to progress into hit-to-lead development with an expectation that more will be identified in Q1 2018.

Expected results until the end of the project

MIMESIS project will launch internally five hit-to-lead optimization programs, resulting in five partially derisked 'Lead' chemical series. These series will be ready for further optimization into potent, selective, well tolerated candidates for clinical testing. ENYO Pharma will explore options to internally optimize or further optimize its best chemical series up to clinical proof of concept in partnership with other pharmaceutical companies.

Conclusion

The MIMESIS project succeeds in offering a pioneering and disruptive technology to identify new starting points for drug candidates in the fields of both infectious diseases and oncology. The approach is also applicable to a large number of pathologies with various etiologies since it targets cellular human pathways.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n° 739086-MIMESIS.

Contact: Jacky Vonderscher, CEO / Eric Meldrum, CSO

mimesis@enyopharma.com

FOLLOW US ON: www.enyopharma.com